This company has been marked as potentially delisted and may not be actively trading. NASDAQ:REXN Rexahn Pharmaceuticals (REXN) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Rexahn Pharmaceuticals Stock (NASDAQ:REXN) 30 days 90 days 365 days Advanced Chart Get Rexahn Pharmaceuticals alerts:Sign Up Key Stats Today's Range N/A50-Day Range$1.81▼$2.2452-Week Range N/AVolume2,579 shsAverage Volume162,968 shsMarket Capitalization$8.11 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewOcuphire Pharma, Inc. engages in the research and development of ophthalmic biopharmaceutical products. It focuses on developing and commercializing therapies for the treatment of several eye disorders. The company was founded by Mina Patel Soouch and Alan R. Meyer in February 2018 and is headquartered in Farmington Hills, MI.Read More… Receive REXN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Rexahn Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address REXN Stock News HeadlinesAurinia Pharmaceuticals Inc AUPHFebruary 16, 2024 | morningstar.comMaxCyte Appoints Douglas Swirsky as Chief Financial OfficerMarch 27, 2023 | benzinga.comDalio heeds Buffett’s warning… [$319 million stake in gold]Dalio bought a gold ETF… I don’t recommend that for the average retail investor. The real upside is in profitable miners selling at deep discounts. I call this price gap the Golden Anomaly — and I’ve put together a full report on my top four picks. June 1, 2025 | Golden Portfolio (Ad)Rexahn: Holes Galore in Serdaxin DataJanuary 1, 2023 | thestreet.comSee More Headlines REXN Stock Analysis - Frequently Asked Questions How were Rexahn Pharmaceuticals' earnings last quarter? Rexahn Pharmaceuticals, Inc. (NASDAQ:REXN) announced its quarterly earnings data on Wednesday, August, 7th. The company reported ($0.61) EPS for the quarter, beating analysts' consensus estimates of ($0.95) by $0.34. When did Rexahn Pharmaceuticals' stock split? Rexahn Pharmaceuticals's stock reverse split on the morning of Friday, April 12th 2019. The 1-12 reverse split was announced on Wednesday, April 10th 2019. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, April 11th 2019. An investor that had 100 shares of stock prior to the reverse split would have 8 shares after the split. What other stocks do shareholders of Rexahn Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Rexahn Pharmaceuticals investors own include TG Therapeutics (TGTX), Inovio Pharmaceuticals (INO), CorMedix (CRMD), SELLAS Life Sciences Group (SLS), Dynavax Technologies (DVAX), Imunon (CLSN) and AcelRx Pharmaceuticals (ACRX). Company Calendar Last Earnings8/07/2019Today6/01/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolNASDAQ:REXN CIK1228627 Webwww.rexahn.com Phone(248) 681-9815FaxN/AEmployees5Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$8.64 million Net MarginsN/A Pretax MarginN/A Return on Equity-72.60% Return on Assets-55.68% Debt Debt-to-Equity RatioN/A Current Ratio3.37 Quick Ratio3.37 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$2.48 per share Price / BookN/AMiscellaneous Outstanding Shares4,483,000Free FloatN/AMarket Cap$8.11 million OptionableOptionable Beta0.98 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free Report This page (NASDAQ:REXN) was last updated on 6/1/2025 by MarketBeat.com Staff From Our PartnersBanks aren’t ready for this altcoin—are you?I've never been more confident about a DeFi opportunity. This isn't about complex trading or risky bets. Th...Crypto 101 Media | SponsoredTrump Just Gave the Green Light to Rewrite Social Security?In a stunning move, President Trump has authorized an AI-led transformation of federal agencies, including Soc...Altimetry | SponsoredThe “supermetal” that could power AIWhile the headlines focus on AI models and chip speed, Elon Musk is investing in the material side of the stor...True Market Insiders | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Robots aren't coming to America in 2025. They are already here. Oxford Economics says, "The Robotics Rev...Weiss Ratings | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredThe Buffett Indicator is screaming, “sell stocks, buy gold”A Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredDo You Believe In President Trump? Answer This 1 QuestionThey said you wouldn’t last—that Bidenflation, Wall Street selloffs, and DEI funds would break your loyalty to...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Rexahn Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Rexahn Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.